Inspire Medical (INSP) Q2 2026 earnings review
Coding Chaos Drives Revenue Contraction Despite Margin Gains
Inspire Medical Systems reported a reversing revenue trajectory, with total sales declining 7.6% YoY to $200.6M in 26Q2. The weakness was isolated to the U.S. market, driven by acute coding and reimbursement friction following the launch of the Inspire V system. However, the underlying unit economics tell a more optimistic story: the Inspire V system drove gross margins up 150 bps to 85.5%, and strong working capital management boosted operating cash flow to $23.2M. Acknowledging the need to pivot, management introduced 'Project Horizon,' a restructuring plan expected to unlock $30M in annualized capacity for growth initiatives. Full-year 2026 revenue guidance was slightly raised but still implies a full-year YoY contraction of approximately 6%.
🐂 Bull Case
The Inspire V system carries a superior margin profile. Gross margins expanded 150 bps YoY to 85.5%, proving that if the company can solve the volume bottlenecks, profitability will scale aggressively.
Project Horizon aims to streamline the organization and consolidate the supply chain. The $30M in annualized savings provides vital capital to reinvest in direct-to-consumer marketing and provider education without burning cash.
🐻 Bear Case
The billing confusion between Medicare (CPT 64582) and commercial payers (CPT 64568) actively destroyed demand in Q2. U.S. revenue declined, breaking years of double-digit growth.
A permanent Category I CPT code for the single-lead Inspire V system is not expected until January 1, 2028. Management must manually hand-hold centers through authorizations for the next 18 months.
⚖️ Verdict: 🔴
Bearish. While gross margin and cash flow are bright spots, a medical device company priced for growth cannot afford a multi-year reimbursement crisis. The 7.6% revenue contraction underscores that administrative hurdles are overpowering clinical demand.
Key Themes
The Innovation Paradox: Inspire V Success Causes Financial Drag
A critical contradiction defines Inspire's current quarter: the new Inspire V system is a clinical triumph—boasting a 79.5% responder rate, eliminating the pressure-sensing lead, and reducing OR time by 20%. Yet, because this innovation disrupted established billing pathways (shifting procedures from CPT 64568 to a confusing mix of 64582 and unlisted codes), U.S. revenue reversed from double-digit growth to a 7.6% decline. Clinical superiority is failing to translate into sales due to administrative paralysis.
Project Horizon: Consolidating to Reinvest
Management announced 'Project Horizon,' a restructuring initiative to streamline the organization and optimize the supply chain. The company will take a $20M-$25M pre-tax hit in 26Q3, primarily from non-cash expenses ($16M-$20M) and severance ($4M-$5M). The goal is to unlock $30M in annualized investment capacity to pump back into revenue-generating initiatives like expanding the field reimbursement team and DTC marketing.
Inspire V Gross Margin Tailwinds
Accelerating profitability at the unit level is a primary driver. The higher sales mix of the Inspire V system over Inspire IV directly drove a 150 basis point increase in gross margin to 85.5%. As legacy inventory clears, this establishes a higher baseline for the company's margin profile once procedure volumes normalize.
WISeR Prior Authorization Headwinds
The government's WISeR program—an AI-reviewed prior authorization requirement for Medicare in six pilot states—continues to create friction. The added layer of scrutiny delays the patient pipeline, compounding the broader CPT coding chaos and contributing to the top-line deceleration.
Macro Impact: The GLP-1 Overhang
Though secondary to the coding crisis, management has historically acknowledged that the widespread adoption of GLP-1 weight loss drugs is altering the sleep apnea market. While weight loss can make more patients eligible for Inspire, in the short term, patients are delaying surgical interventions to try pharmaceutical weight loss first, dampening near-term demand.
International Sales Buffer the U.S. Decline
While the U.S. market contracted due to domestic coding issues, the international segment provided a growth offset. Although a smaller portion of the overall business, international adoption relies on distinct regulatory and reimbursement frameworks, proving that the demand for the therapy remains intact when administrative pathways are clear.
Other KPIs
Accelerating. Cash generated from operations surged compared to the $2.7 million generated in 25Q2. Management attributed this to improved working capital management, particularly better collections in accounts receivable and tighter inventory controls. This cash generation fortifies the balance sheet ($415.2M in cash/investments) as the company navigates the current revenue slump.
Decelerating. Operating expenses decreased 7.4% YoY. This was driven by two factors: a tough YoY comparison due to accelerated stock-based compensation recorded in 25Q2, and a deliberate reduction in marketing expenses. The reduction in marketing highlights a strategic pause, likely because driving patients into a broken authorization funnel yields poor ROI.
Guidance
Reversing. Management raised the bottom end of the range from Q1 ($825-$875M), but this still implies a YoY contraction of roughly 4% to 8% compared to FY25 revenue of $912M. It marks a severe deceleration from historical +12-14% growth rates, reflecting the deep impact of the ongoing coding crisis.
Stable to Accelerating. Raised from previous guidance of 2.0% - 4.0%. This reflects the immediate benefits of Inspire V's stronger gross margin and the anticipated savings from Project Horizon. The company is actively protecting its bottom line while the top line suffers.
Stable. Raised from prior expectations of $0.75 - $1.25. The high GAAP effective tax rate (estimated at 95%-100%) due to stock-based compensation shortfalls will crush GAAP EPS, but the underlying cash generation and adjusted earnings remain defensive.
Key Questions
Project Horizon Specifics
Can you provide granular details on the 'supply chain consolidation' under Project Horizon? Are you moving away from certain suppliers, and does this introduce any near-term inventory risk for Inspire V?
Coding Resolution Timeline
With the new Category I CPT code not expected until 2028, what specific milestones are you tracking with the AHA and MACs to unify the interim billing process? Are there any states where this is fully resolved?
Marketing Expense Calibration
Operating expenses fell due to lower marketing spend. Given the $30M in reinvestment capacity unlocked by Project Horizon, when will you feel confident enough in the prior authorization funnel to ramp DTC marketing back up?
GLP-1 Quantification
In previous quarters, you mentioned GLP-1s acting as a headwind. With the 7.6% revenue decline in Q2, how much of that drop can be attributed to GLP-1 delays versus the coding and WISeR program issues?